Valuation: Scholar Rock Holding Corporation

Market Cap 6.33B 5.56B 5.12B 4.77B 8.99B 602B 9.18B 61.55B 23.85B 295B 23.77B 23.26B 1,028B P/E 2026 *
-16.6x
P/E 2027 * -20.7x
Enterprise Value 6.03B 5.29B 4.87B 4.54B 8.56B 573B 8.74B 58.61B 22.71B 281B 22.64B 22.15B 979B EV / Sales 2026 *
926x
EV / Sales 2027 * 40x
Free-Float
99.22%
Yield 2026 *
-
Yield 2027 * -
1 day-3.93%
1 week+0.97%
Current month-3.93%
1 month+11.50%
3 months+7.07%
6 months+19.95%
Current year+19.95%
1 week 52.84
Extreme 52.84
56.54
1 month 43.23
Extreme 43.23
56.54
Current year 38.75
Extreme 38.75
56.54
1 year 27.07
Extreme 27.07
56.54
3 years 5.93
Extreme 5.93
56.54
5 years 4.32
Extreme 4.325
56.54
10 years 4.32
Extreme 4.325
70
Manager TitleAgeSince
Chief Executive Officer 59 2025-04-26
Director of Finance/CFO 62 2025-04-26
Chief Operating Officer 58 2025-04-26
Director TitleAgeSince
Chairman 59 2017-06-30
Director/Board Member 53 2014-07-31
Director/Board Member 78 2016-09-30
Date Insider Type Main position Quantity % Market Cap.
06-03Free

Director

11,149 0.0097%
06-03Free

Director

11,149 0.0097%
06-03Free

Director

11,149 0.0097%
Change 5-day change 1-year change 3-year change Capi.($)
-3.93%+0.97%+56.52%+600.80% 6.59B
-2.19%+6.01%+66.90%+123.30% 57.65B
+0.55%+8.49%+77.09%+100.93% 55.14B
+0.93%+4.11%-12.64%-12.98% 23.53B
+0.36%+3.42%+9.61%+407.11% 23.11B
+3.64%+8.40%+39.88%-5.83% 18.14B
+0.28%+5.51%+36.93%-30.23% 16.84B
+1.49%+17.24%+174.91%+344.55% 15.65B
-0.83%+2.06%+23.70%+182.37% 13.68B
+6.60%+12.51%+41.09% - 12.97B
Average +0.68%+6.30%+51.40%+190.00% 24.33B
Weighted average by Cap. +0.31%+6.41%+54.85%+143.31%

Financials

2026 *2027 *
Net sales 6.51M 5.72M 5.26M 4.9M 9.25M 619M 9.44M 63.3M 24.52M 304M 24.45M 23.92M 1.06B 149M 131M 121M 113M 212M 14.21B 217M 1.45B 563M 6.98B 561M 549M 24.28B
Net income -410M -360M -331M -309M -582M -38.95B -594M -3.98B -1.54B -19.12B -1.54B -1.51B -66.54B -356M -313M -288M -268M -506M -33.87B -516M -3.46B -1.34B -16.63B -1.34B -1.31B -57.87B
Net Debt -302M -265M -244M -227M -429M -28.72B -438M -2.94B -1.14B -14.1B -1.13B -1.11B -49.06B -356M -312M -287M -268M -505M -33.81B -515M -3.46B -1.34B -16.59B -1.34B -1.31B -57.75B
Logo Scholar Rock Holding Corporation
Scholar Rock Holding Corporation is a biopharmaceutical company. The Company focuses on improving the lives of children and adults with spinal muscular atrophy (SMA) and additional rare, severe and debilitating neuromuscular diseases. Its pipeline product candidates include apitegromab, a subcutaneous formulation of apitegromab, and SRK-439. The Apitegromab is an investigational fully human, intravenously administered monoclonal antibody designed to inhibit myostatin activation by selectively binding the pro- and latent forms of myostatin in the skeletal muscle. The SRK-439, is an investigational, subcutaneously administered fully human anti-pro/latent myostatin antibody that has high inhibitory potency while maintaining selectivity towards myostatin. Its early-stage pipeline includes additional programs for the treatment of patients with rare, severe, and debilitating neuromuscular diseases.
Employees
289
Date Price Change Volume
26-07-01 US$52.84 -3.93% 1,304,387
26-06-30 US$55.00 +0.07% 1,688,113
26-06-29 US$54.96 +0.37% 2,095,150
26-06-26 US$54.76 +1.80% 7,570,575
26-06-25 US$53.79 +2.79% 2,376,814
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
18
Last Close Price
52.84USD
Average target price
59.31USD
Spread / Average Target
+12.25%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. SRRK Stock